Skip to main content

Danielle Blunt

Oct 19, 2026

12:15
So Daniel, what are the methods of measuring ctDNA that are out commercially available or in research available? And what are the methods that look most promising to you in PTCL?
12:32
I think the ctDNA is probably the most broadly applicable approach with next-generation sequencing used to identify and track tumor-derived variants in the plasma.
12:44
But we know that PTCL is such a heterogeneous disease and offers a lot of biological challenges.
12:53
It certainly won't be one size fits all.
12:56
So one approach is to do the next generation sequencing of the ctDNA where you identify mutations associated with the lymphoma, and then you can track those longitudinally in the plasma.
13:08
The difficulty with this is making sure that the signal that you're actually following belongs to the lymphoma.
13:15
And a really good example in peripheral T cell is neural T follicular helper cell lymphomas, where we know that there's a lot of more myeloid-based mutations that can be driving clonal hematopoiesis in the background, mutations such as TET2, DNM T3A, Rho A, IDH2.

12 MINS LATER

25:46
Danielle,

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click “Accept All” to consent, or “Decline non-essential” to opt out of non-essential cookies. Read our Privacy Policy.